Oryzon Genomics SA (ORN) Stock Statistics & Valuation Metrics
Total Valuation
Oryzon Genomics SA has a market cap or net worth of EUR 198.99M. The enterprise value is EUR 230.85M.
- Market Cap
- EUR 198.99M
- Enterprise Value
- EUR 230.85M
Share Statistics
Oryzon Genomics SA has 84,332,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 84,332,150
- Owned by Insiders
- ―
- Owned by Institutions
- 0.22%
Financial Efficiency
Oryzon Genomics SA’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -2.23%.
- Return on Equity (ROE)
- -0.02
- Return on Assets (ROA)
- -0.02
- Return on Invested Capital (ROIC)
- -2.23%
- Return on Capital Employed (ROCE)
- -0.05
- Revenue Per Employee
- 0
- Profits Per Employee
- -56.64K
- Employee Count
- 46
- Asset Turnover
- 0.00
- Inventory Turnover
- 35.89
Valuation Ratios
The current PE Ratio of Oryzon Genomics SA is -77.82. Oryzon Genomics SA’s PEG ratio is -1.33.
- PE Ratio
- -77.82
- PS Ratio
- 0.00
- PB Ratio
- 1.57
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- -1.33
Income Statement
In the last 12 months, Oryzon Genomics SA had revenue of 0 and earned -2.61M in profits. Earnings per share was -0.04.
- Revenue
- 0
- Gross Profit
- -133.91K
- Operating Income
- -6.42M
- Pretax Income
- -5.60M
- Net Income
- -2.61M
- EBITDA
- -6.29M
- Earnings Per Share (EPS)
- -0.04
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Oryzon Genomics SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -1.29%
Stock Price Statistics
- Beta
- 0.55
- 52-Week Price Change
- -30.00%
- 50-Day Moving Average
- 2.65
- 200-Day Moving Average
- 2.82
- Relative Strength Index (RSI)
- 36.45
- Average Volume (3m)
- 20
Important Dates
Oryzon Genomics SA upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 22, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Oryzon Genomics SA as a current ratio of 1.95, with Debt / Equity ratio of 11.32%
- Current Ratio
- 1.95
- Quick Ratio
- 1.94
- Debt to Market Cap
- 0.05
- Net Debt to EBITDA
- 2.61
- Interest Coverage Ratio
- -10.55
Taxes
In the past 12 months, Oryzon Genomics SA has paid -2.99M in taxes.
- Income Tax
- -2.99M
- Effective Tax Rate
- 0.53
Enterprise Valuation
Oryzon Genomics SA EV to EBITDA ratio is -27.74, with an EV/FCF ratio of 0.00.
- EV to Sales
- 0.00
- EV to EBITDA
- -27.74
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
Oryzon Genomics SA has EUR 22.12M in cash and marketable securities with EUR 7.10M in debt, giving a net cash position of EUR 15.01M billion.
- Cash & Marketable Securities
- EUR 22.12M
- Total Debt
- EUR 7.10M
- Net Cash
- EUR 15.01M
- Net Cash Per Share
- EUR 0.18
- Tangible Book Value Per Share
- EUR 0.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Oryzon Genomics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 53.50%
